Speaker Profile
M.D., Ph.D., Associate Professor of Medicine, MayoClinic / Phenomix
Biography
Dr. Acosta is a physician, scientist, inventor, and entrepreneur. Board certified in Internal Medicine, Gastroenterology, and Obesity Medicine. He is an Associate Professor of Medicine and co-directs the Nutrition Obesity Research Program at the Mayo Clinic. His research focus on precision medicine for obesity with the aim to identify the right therapy for the right patient. His research is supported by the NIH, many foundations and industry. He is a recognized national and international speaker with many patents, more than 160 peer-reviewed publications, including publications in the Lancet, Gut and Gastroenterology, and many chapters. His works has been featured in the New York Times, Time, NPR, among others. He won the 40-under-40 innovation award at Minneapolis Business Journal and Tekne Award. He co-founded Phenomix Sciences and launched the first-of-its-kind diagnostic test to predict response to GLP-1s and other obesitymetabolic interventions. Time Magazine selected as one of the best inventions of 2024.
Talk
Machine-learning Assisted Gene Risk Score Predicts Response to GLP-1s
The response to GLP-1s is highly variable. We created a Machine-learning Assisted Gene Risk Score Predicts Response to GLP-1s and other obesity and metabolic interventions. This first-of-its-kind diagnostic test, called MyPhenome, was launched in 2024.
Clinical Dx Showcase:
MayoClinic / Phenomix
Phenomix Sciences is a AI-enabled Precision Medicine for Obesity and Metabolic Diseases.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
